An important issue, according to Dr Kolodziej, national medical director of oncology strategy at Aetna, is whether cost could potentially be a barrier for true breakthrough medications such as the PD-1s. During the second segment of a one-on-one interview conducted at the Oncology Stakeholders Summit, Spring 2015 series, he emphasizes the importance of biomarkers to help identify patients who will most benefit from the treatment. Like in hepatitis C, payers want to better understand who is the right patient to treat with high-cost breakthrough drugs and what is the right time to treat. Dr Kolodziej states that the goal with breakthrough therapies is to lower or reduce the barriers that patients face in receiving them.
Dr Feinberg, vice president and chief medical officer at Cardinal Health Specialty Solutions, agrees that although cost is a barrier for every agent, the PD-1 agents’ high efficacy and low toxicity override, to an extent, the cost barrier.
The new CMMI Oncology Care model concerns both Drs Kolodziej and Feinberg in that it does not adequately compensate for expenses incurred when appropriately using innovative products. If a physician prescribes PD-1 treatment, the total cost of care will be higher, and the oncology practice will be disadvantaged. If the CMMI Oncology Care model is based on an episode-of-care or bundled care, breakthrough therapeutics that raise the aggregate cost to the practice will not be preferred. Dr Kolodziej explains that it may take a couple of years to find that savings are not being generated, owing to the high cost of innovative agents, forcing CMMI to adjust the model.
Watch our related Peer Exchange, Oncology Stakeholders Summit, Spring 2015.
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Reviving the Classics: The Role of Older Medications in Modern Dermatology
March 9th 2025Older, generic medications, including ones for cyclosporine, nicotinamide, and dapsone, can effectively treat patients with various dermatological conditions while helping to reduce insurance and cost barriers.
Read More
Myasthenia Gravis Care Overlooks Speech and Swallowing Dysfunction
March 9th 2025Myasthenia gravis is a neuromuscular junction disorder with a hallmark of progressive muscle weakness and frequent manifestation of otolaryngologic dysfunction, such as difficulty swallowing and speech disorder.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Reviving the Classics: The Role of Older Medications in Modern Dermatology
March 9th 2025Older, generic medications, including ones for cyclosporine, nicotinamide, and dapsone, can effectively treat patients with various dermatological conditions while helping to reduce insurance and cost barriers.
Read More
Myasthenia Gravis Care Overlooks Speech and Swallowing Dysfunction
March 9th 2025Myasthenia gravis is a neuromuscular junction disorder with a hallmark of progressive muscle weakness and frequent manifestation of otolaryngologic dysfunction, such as difficulty swallowing and speech disorder.
Read More
2 Commerce Drive
Cranbury, NJ 08512